LAMPRENE
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Dec 1986
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 9h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LAMPRENE is an oral small-molecule capsule approved in 1986 for an unspecified indication under Novartis sponsorship. The exact mechanism of action and therapeutic area are not publicly detailed in available data. This product represents a legacy pharmaceutical asset in the modern portfolio.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), signaling transition planning and potential team restructuring.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Lamprene Multiple Patient Program
Non-Tuberculous Mycobacterial (NTM) Infections
Career Relevance
LAMPRENE offers minimal career growth opportunity given zero linked job openings and approaching loss of exclusivity. Professionals assigned to this product should anticipate portfolio transition and focus on managed decline and cost-optimization initiatives rather than expansionary work.
Brand Manager
Worked on LAMPRENE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.